What changed
$VRTX — Develops therapies for cystic fibrosis and other serious diseases.
🎯 Q1 FY26 | Rev $3B | EPS $4.47 vs $4.31 🟢 | Margin 38.1%
💡 Consensus expects steady CF revenue growth and pipeline optionality to support a ~30x forward P/E. However, the market may be underestimating near-term margin pressure from rising R&D spend (32% of revenue) and potential delays in non-CF pipeline readouts (e.g., VX-548 for pain). The 3.8% EPS beat is modest and already priced in.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 10% to $490 (25x FY26 EPS of $19.15) vs downside 15% to $380 (20x EPS on pipeline disappointment). Ratio ~0.7:1.
🔮 Catalyst: Next catalyst: Q2 2026 earnings (late July) – watch for CF revenue growth vs guided $3.2B consensus and any pipeline updates (VX-548 Phase 3 data). Failure signal: CF revenue miss or pipeline setback.
Also in play: $REGN $BIIB $AMGN $GILD $INCY $LONN